Other Cancer News

Get the latest cancer news and research. Sort by cancer type or read the current headlines to learn what’s happening in the science of cancer detection and treatment, as well as healthy living tips for dealing with cancer.

Oct

01

Data From National Cancer Institute Advance Knowledge In Merkel Cell Cancer

In this recently published article, scientists in the United States conducted a study To expedite improved understanding, diagnosis, treatment, and prevention of Merkel cell carcinoma (MCC), a rare malignancy of cutaneous neuroendocrine cells that has a 28% 2-year mortality rate.

Oct

01

Study Reveals Two Out Of Three Prostate Cancer Patients Do Not Need Treatment

In the largest study of its kind, the international team of pathologists studied an initial 4,000 prostate cancer patients over a period of 15 years to further understanding into the natural progression of the disease and how it should be managed. The research, published in the British Journal of Cancer, could be used to develop a blood test to distinguish between aggressive and non-aggressive forms of prostate cancer.

Oct

01

Whole-Brain Radiotherapy After Surgery Or Radiosurgery Not Recommended For Brain Metastases

Whole-brain radiotherapy should not be given routinely to all patients whose cancer has spread to the brain, say researchers who found that using it after surgery or radiosurgery in patients with a limited number of brain metastases and stable cancer in the rest of the body did not extend lives or help patients remain functionally independent for longer.

Sep

29

Plexxikon Announces First Patient Dosed In First Of Two Pivotal Trials Of PLX4032 For Metastatic Melanoma

Plexxikon Inc. announces that enrollment has been initiated and the first patient has been treated in the first of two pivotal trials of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer- causing mutation occurring in about 50 percent of melanomas and about eight percent of all solid tumors.

Sep

29

Drug That Crosses Blood-Brain Barrier Reduces Formation Of Brain Metastases In Mice

The drug vorinostat is able to cross the blood- brain barrier and reduce the development of large metastatic tumors in mice brains by 62 percent when compared to mice that did not receive the drug, according to a new study.

Sep

29

Personalized, Gene-Based Risk Testing For Lung Cancer Gives New Tool To Help Smokers Quit

Smokers who learn their personal risk of lung cancer through gene-based risk assessment are more likely to be motivated to quit their habit, according to Dr. W. Jeffrey Allard, clinical affairs director of Synergenz Bioscience Ltd.

Sep

27

Researchers Create Microchip That Can Detect Type And Severity Of Cancer

U of T researchers have used nanomaterials to develop a microchip sensitive enough to quickly determine the type and severity of a patient's cancer so that the disease can be detected earlier for more effective treatment.

Sep

26

Lung Cancer Survivors Fight Societal Stigma

The doctors told Susan Smedley Gerber that her lung cancer wasn't caused by smoking but in many ways it didn't matter. She found herself facing the same stigma and same reactions that thousands of lung cancer patients fight in addition to their cancer.

Sep

25

Chemicals Linked To Testicular Cancer

Higher levels of environmental chemicals in breast milk are linked to a higher incidence of testicular cancer, researchers in Denmark found.

Sep

24

BioVex Agrees SPA With The FDA For A Pivotal Phase III Study With OncoVEX (GM-CSF) In Head And Neck Cancer

BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, announced that the U.S. Food and Drug Administration (FDA) has approved the design of a single, pivotal, Phase III clinical trial evaluating its lead product, OncoVEX (GM-CSF), for the first-line treatment of patients with squamous cell cancer of the head and neck.

Page(s): Prev 12...5 6 7 8 9 10 11 ...542543 Next 

We care about your feedback. Let us know how we can improve your CancerCompass experience.